TTUHSC, DCOA Commercial Technology Venture Launches Website

ExperImmune, a technology partnership between the Development Corporation of Abilene (DCOA) and the Center for Immunotherapeutic Development at Texas Tech University Health Sciences Center (TTUHSC), announced today the launch of its website, www.ExperImmune.com. The site provides users access to a number of areas, including ExperImmune’s immunology-based research services and product pipeline.

“Visitors will experience a vibrant and user-friendly website that showcases our company’s ability to provide unparalleled research and development services to the academic, biotech and pharmaceutical sectors,” said Jon Weidanz, Ph.D., ExperImmune’s director and chief scientist. “We have also included information related to the development of a number of our immunodiagnostic and immunotherapeutic products, which will become available in the near future.”

Weidanz is also professor and chair for the Department of Immunotherapeutics and Biotechnology at TTHUSC School of Pharmacy in Abilene.

To enhance a customer’s experience, ExperImmune intends to maintain a Web portal directly on the site that will provide contracted partners with secure access to documents and data files related to their specific research projects.

ExperImmune is an immunology-focused company that provides third-party validation services, product development and due diligence to academic-based institutions, biotechnology companies, pharmaceutical companies and investment groups. This enterprise between the DCOA and TTUHSC allows the company to operate with low overhead and provide its customers with services and products at a relatively low cost, thereby maximizing research dollars.

In addition to Weidanz, ExperImmune’s team includes fellow scientists with expertise in disciplines like cancer biology, infectious disease, molecular and cellular immunology, proteomics and biomaterials science.

For more information, go to www.ExperImmune.com.

 For more breaking news and experts, follow @ttuhscnews on Twitter.